A new study published in the January 2015 Investigative Ophthalmology & Visual Science has shared alarming news regarding patients who suffer from long-term or chronic hypertension. Information gleaned from studies has revealed that people who are diagnosed with hypertension and who do not treat their condition are at a heightened risk for glaucoma. Ophthalmologists and[…]
Long Term Hypertension Leads to Glaucoma and Brinzolamide is a Viable Treatment Option
Anti-Hypertensive, Drug Research & Development API Tags: glaucomahypertensionintraocular pressure May 29, 2015
FDA Approves Dorzolamide for Lowering Intraocular Pressure
Drug Research & Development API, FDA Approved 2014, OTC and Compounding Product Tags: glaucomahypertensionintraocular pressure May 04, 2015
In late 2014 the FDA approved Dorzolamide Hydrochloride, to be used in conjunction with Timolol Maleate for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Known as the brand name eye drop Cosopt Opthamolic Solution, which is marketed by Lannett Company Inc., this solution has proven to be both[…]
Droxidopa Approved for Parkinson’s-Related Hypotension
Anti-Parkinsons, Drug Research & Development API, FDA Approved 2014 Tags: hypertension Feb 28, 2014
The FDA recently approved Droxidopa, known as the brand name Northera, to treat neurogenic orthostatic hypotension, which is a common complication of Parkinson’s disease. Neurogenic orthostatic hypotension or NOH is an uncommon but dangerous drop in blood pressure that presents upon standing. Patients with NOH exhibit symptoms like severe dizziness, a faint feeling, weakness, fatigue[…]
Eplerenone for Acute ST-Segment Elevation Myocardial Infarction
Drug Research & Development API, Hormonal Agent, Patent Expiration 2019 Tags: congestive heart failurehypertensionPfizer Nov 13, 2013
Exciting results were revealed in Mid-March of 2013 when the REMINDER trial touted the success of Eplerenone for treating acute ST-Segment Elevation Myocardial Infarction, also known as STEMI. The results from this study were presented at the 62nd Annual Scientific Session of the American College of Cardiology, by Pfizer, who markets Inspra which is the[…]
Breaking News: Riociguat FDA Approval Brings Relief
Cardiovascular Agent, Drug Research & Development API Tags: Europehypertension Oct 10, 2013
Riociguat, CAS# 625115-55-1, was approved yesterday by the FDA for the treatment of thromboembolic pulmonary hypertension. Known as the brand name Adempas, Riociguat has proven in trials to be an efficacious treatment option for adults with both persistent and recurrent thromboembolic pulmonary hypertension. The patient population suffering from chronic (CTPH) or recurrent thromboembolic pulmonary hypertension is[…]
Patients Find Help Preventing Gout with Febuxostat
Anti-Inflammatory, Drug Research & Development API, FDA Approved 2009 Tags: hypertension Dec 26, 2012
As the most common inflammatory arthritis among men, gout is an inconsistent condition. Gout may remit for long periods, present as flare-ups for days or weeks, or be chronic for months or longer. The advent of Febuxostat CAS# 144060-53-7, has offered hope to patients with this debilitating form of arthritis. As an effectual treatment for[…]
Azilsartan is a Next Generation ARB Blockbuster
Drug Research & Development API, FDA Approved 2011 Tags: hypertension Nov 09, 2012
On February 25, 2011 the FDA approved Azilsartan for the treatment of hypertension. Known as the brand name Edarbi marketed by Takeda Pharmaceuticals, Azilsartan has shown to be extremely effective in clinical studies. When compared with other FDA approved medications for hypertension, particularly valsartan (Diovan) and olmesartan (Benicar), Azilsartan (Edarbi) proved to be more efficacious[…]
Carvedilol Phosphate is a Beta-Blocker to Watch
Bulk Active Ingredient, Cardiovascular Agent, Drug Research & Development API, Patent Expiration 2016 Tags: beta-blockerchronic heart failureheart failurehypertension Sep 04, 2012
Carvedilol Phosphate, CAS number 72956-09-3, is known as the blockbuster medication Coreg CR. GlaxoSmithKline holds the patent for Coreg CR until February 7, 2016. Useful for treating patients with hypertension and mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, carvedilol phosphate is available for research and development from LGM Pharma. In the group of[…]
Current Research Continues to Tout the Benefits of Nebivolol
Cardiovascular Agent, Drug Research & Development API, Patent Expiration 2015 Tags: antihypertensivebeta-blockerhypertension Jul 13, 2012
Nebivolol, CAS# 99200-09-6, is recognized as the brand name anti-hypertensive drug Bystolic, which is marketed by Forest Pharmaceuticals, Inc. This beta-blocker powerhouse has a patent expiration of June 2, 2015, and is projected to become a widely used generic treatment for chronic hypertension. Current dosages of Bystolic, or nebivolol, 2.5, 5, 10, and 20 milligram[…]
Established Carvedilol Poised to be a Leading Generic Beta-Blocker
Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2015, Respiratory Tract Agent Tags: beta-blockerheart failurehypertension Jun 21, 2012
Carvedilol, CAS# 72956-09-3, is known as the brand name Coreg, which is marketed by GlaxoSmithKline. The patent for Coreg will expire on June 7, 2015, making way for a generic market. As a beta-blocker used to treat hypertension and heart failure, carvedilol is also often prescribed to treat and prevent heart attack symptoms. Carvedilol is[…]
- 1
- 2
